Highlights Jul 13 - Jul 19, 2026
new every Sunday
FDA guidance, a major pharmaceutical acquisition, and debate over psilocybin care models put regulation and commercialization at the center of the week. New research also examined lasting psilocybin outcomes, LSD brain dynamics, and emerging drug risks.
-
01
FDA issues final guidance for psychedelic drug development and schedules a September public hearing on the future of psychedelic therapies
FDA guidance sets expectations for trial design, blinding, safety, and support, while a September hearing opens the wider policy debate.
-
02
Eli Lilly agrees to buy psychedelics drugmaker Atai Beckley for $2.8 billion, pushing large pharma deeper into clinical psychedelic development
Lilly's $2.8 billion purchase of Atai Beckley marks a major pharmaceutical bet on psychedelic drug development and commercialization.
-
03
Compass Pathways' push for scalable psilocybin treatment centers on whether psychotherapy should remain essential to COMP360-assisted care
Compass's delivery model could decide whether COMP360 scales as therapist-intensive care or a leaner, more widely reimbursable protocol.
-
04
New study links psilocybin-assisted therapy to lasting reductions in depression symptoms and changes in brain network flexibility over several months
Psilocybin-assisted therapy was linked to months-long depression relief and changes in brain-network flexibility over time.
-
05
Brain scans reveal how LSD desynchronizes local neural activity and reorganizes large-scale brain dynamics linked to altered conscious experience
Brain imaging found that LSD reduces local neural synchrony while increasing longer-range coordination linked to altered consciousness.
-
06
Uebersichtsarbeit zum Fliegenpilz - Amanita muscaria gewinnt im Umfeld neuer psychoaktiver Substanzen an Bedeutung, mit Fokus auf Konsumformen, Risiken und Wissensluecken
A review consolidates evidence on Amanita muscaria's pharmacology, consumption patterns, risks, and major gaps in current knowledge.
-
07
In-silico-Studie bewertet das toxikologische Profil von PCP-Analoga als neue psychoaktive Substanzen und vergleicht potenzielle Risiken mit bekanntem PCP
Computational toxicology compares emerging PCP analogues with PCP, providing early risk signals where human safety data remain scarce.
-
08
Gabon places iboga at the center of cultural sovereignty, linking Bwiti tradition, conservation, and control over how a sacred plant enters global psychedelic markets
Gabon is tying iboga access to Bwiti authority, conservation, cultural sovereignty, and benefit-sharing in expanding global markets.